Welcome to our dedicated page for uniQure N.V. SEC filings (Ticker: QURE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on uniQure N.V.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into uniQure N.V.'s regulatory disclosures and financial reporting.
State Street Corporation reports shared beneficial ownership of 2,260,512 shares of Uniqure N.V. common stock, representing 3.6% of the class as reported on 03/31/2026. The filing lists shared voting power of 2,230,049 and identifies affiliated investment adviser entities.
The filing is a Schedule 13G disclosure showing passive/beneficial ownership by institutional holders and names SSGA Funds Management, State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company and State Street Global Advisors, Ltd. as related entities.
Uniqure N.V. submitted a Form 144 notice reporting proposed sales of Ordinary Shares to be effected through Citigroup Global Markets, Inc. on 05/08/2026. The filing lists 45,000 (figure present) and details 20,000 vested shares and 25,000 shares from option exercises.
FMR LLC filed an amendment to Schedule 13G reporting beneficial ownership of 1,743,807.87 shares of UNIQURE N.V. common stock, representing 2.8% of the class. The filing lists sole dispositive power for 1,743,807.87 shares and sole voting power of 1,741,237 shares. The cover names Abigail P. Johnson in connection with FMR LLC and references an exhibit for a 13d-1(k)(1) agreement.
uniQure N.V. reported first quarter 2026 results showing a net loss of $53.5 million, or $0.85 per share, compared with a $43.6 million loss a year earlier. Revenue rose to $3.6 million from $1.6 million, mainly from higher license revenue.
The company ended March 31, 2026 with $586.6 million in cash, cash equivalents and current investment securities and expects this to fund operations into the second half of 2029. Research and development expenses fell to $29.2 million, while selling, general and administrative expenses increased to $20.1 million, reflecting hiring for AMT-130 commercial planning.
uniQure highlighted pipeline progress, including ongoing FDA interactions for AMT-130 in Huntington’s disease with a Type B meeting planned in the second quarter of 2026 and a targeted UK marketing authorization application submission in the third quarter of 2026. Additional 2026 updates are expected from AMT-260 in mesial temporal lobe epilepsy, AMT-191 in Fabry disease and AMT-162 in SOD1 ALS.
Aberdeen Group plc and abrdn Inc. report beneficial ownership of 5,306,386 ordinary shares of uniQure N.V., representing 8.49% of the class. The filing states shared voting and dispositive power for 5,306,386 shares. The disclosure is submitted by a parent and intermediate holding structure and signed by a Major Shareholding Reporting Analyst on 03/31/2026.
uniQure N.V. announced a successful pre-submission meeting with the UK Medicines and Healthcare products Regulatory Agency for AMT-130, its investigational gene therapy for Huntington’s disease. The company plans to submit a UK Marketing Authorization Application in the third quarter of 2026.
The planned submission will be based on three-year data from ongoing U.S. and European Phase I/II trials, where high-dose AMT-130 showed a statistically significant 75% slowing of disease progression on a composite Huntington’s scale versus a matched external control (p=.003) and was generally well-tolerated with a manageable safety profile.
uniQure has also been granted a Type B meeting with the U.S. Food and Drug Administration in the second quarter of 2026 to discuss a potential Phase III trial design and the statistical analysis plan for a four-year data readout expected in the third quarter of 2026, while pursuing additional ex-US regulatory pathways.
uniQure N.V. is asking shareholders to vote at its 2026 Annual General Meeting on June 10, 2026 in Amsterdam on financial statements, director reappointments and several governance and capital proposals.
Key items include adopting the 2025 Dutch statutory annual accounts, granting discharge to board members, reappointing three non-executive directors, and appointing KPMG Accountants N.V. as external auditor for 2026. The board seeks authority for 18 months to issue up to 12,400,000 ordinary shares, to limit or exclude pre-emptive rights on those issuances, and to repurchase up to 10% of issued share capital. Shareholders are also asked to approve, on an advisory basis, 2025 executive pay and to hold future “say‑on‑pay” votes every year, amend and restate the 2014 Share Incentive Plan with an additional 350,000 shares (bringing total plan capacity to 11,040,279 shares), and approve several amendments to the Articles of Association, including adopting the Dutch large company regime, increasing authorized share capital and adding a federal forum selection clause. Record date is May 13, 2026, with approximately 63,065,985 ordinary shares entitled to one vote each; the board recommends voting “FOR” all proposals and “ONE YEAR” on say‑on‑pay frequency.
uniQure N.V. convenes its 2026 Annual General Meeting on June 10, 2026 to vote on routine Dutch-law items and governance actions, including adoption of the 2025 Dutch statutory annual accounts, discharge of the Board, reappointments of three non-executive directors, authorizations to issue up to 12,400,000 ordinary shares (approx. 19.7%), authority to exclude or limit pre-emptive rights, an 18‑month share repurchase authorization up to 10% of issued capital, appointment of KPMG as auditor, and an amendment to the 2014 Share Incentive Plan increasing the reserve to 11,040,279 shares. The record date is May 13, 2026, and approximately 63,065,985 Ordinary Shares were expected outstanding as of that date.